HK1051368A1 - Beta-carboline derivatives useful as inhibitors of phosphodiesterase - Google Patents

Beta-carboline derivatives useful as inhibitors of phosphodiesterase

Info

Publication number
HK1051368A1
HK1051368A1 HK03103637A HK03103637A HK1051368A1 HK 1051368 A1 HK1051368 A1 HK 1051368A1 HK 03103637 A HK03103637 A HK 03103637A HK 03103637 A HK03103637 A HK 03103637A HK 1051368 A1 HK1051368 A1 HK 1051368A1
Authority
HK
Hong Kong
Prior art keywords
phosphodiesterase
inhibitors
beta
derivatives useful
carboline derivatives
Prior art date
Application number
HK03103637A
Other languages
English (en)
Inventor
Zhihua Sui
Mark J Macielag
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of HK1051368A1 publication Critical patent/HK1051368A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK03103637A 2000-05-17 2003-05-22 Beta-carboline derivatives useful as inhibitors of phosphodiesterase HK1051368A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20466700P 2000-05-17 2000-05-17
PCT/US2001/014357 WO2001087038A2 (en) 2000-05-17 2001-05-03 β-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE

Publications (1)

Publication Number Publication Date
HK1051368A1 true HK1051368A1 (en) 2003-08-01

Family

ID=22758909

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03103637A HK1051368A1 (en) 2000-05-17 2003-05-22 Beta-carboline derivatives useful as inhibitors of phosphodiesterase

Country Status (32)

Country Link
US (2) US6492358B2 (es)
EP (1) EP1289985B1 (es)
JP (1) JP5014551B2 (es)
KR (1) KR20030031482A (es)
CN (1) CN1255403C (es)
AR (1) AR028576A1 (es)
AT (1) ATE256127T1 (es)
AU (2) AU2001261167B2 (es)
BG (1) BG66141B1 (es)
CA (1) CA2409715C (es)
CZ (1) CZ20023934A3 (es)
DE (1) DE60101479T2 (es)
DK (1) DK1289985T3 (es)
ES (1) ES2211806T3 (es)
GE (1) GEP20053511B (es)
HK (1) HK1051368A1 (es)
HR (1) HRP20020910B1 (es)
HU (1) HUP0302412A3 (es)
IL (2) IL152873A0 (es)
MX (1) MXPA02011426A (es)
MY (1) MY128479A (es)
NO (1) NO324251B1 (es)
NZ (1) NZ522731A (es)
PL (1) PL205507B1 (es)
PT (1) PT1289985E (es)
RU (1) RU2271358C2 (es)
SK (1) SK16972002A3 (es)
TR (1) TR200302309T4 (es)
TW (1) TWI286553B (es)
UA (1) UA74826C2 (es)
WO (1) WO2001087038A2 (es)
ZA (1) ZA200210111B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1347759B1 (en) * 2000-12-08 2005-06-29 Smithkline Beecham Corporation Antibacterial compounds
US6900220B2 (en) * 2001-01-02 2005-05-31 Syntex (U.S.A.) Llc Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
EP1360185B1 (en) * 2001-02-12 2005-08-24 Lilly Icos LLC Carboline derivatives
WO2002064591A2 (en) * 2001-02-12 2002-08-22 Lilly Icos Llc Carboline derivatives
CA2441792C (en) * 2001-04-25 2010-08-03 Lilly Icos Llc Carboline derivatives as inhibitors of phosphodiesterase 5 (pdes) for the treatment of cardiovascular diseases and erectile dysfunction
JP2004536816A (ja) 2001-06-05 2004-12-09 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅ５阻害剤としてのカルボリン誘導体
EP1397361B1 (en) * 2001-06-21 2006-08-09 Lilly Icos LLC Carboline derivatives as pdev inhibitors
DK1448562T3 (da) 2001-11-14 2007-09-24 Ortho Mcneil Pharmaceutical Co Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
BRPI0307699A2 (pt) * 2002-02-07 2015-06-16 Gtx Inc Tratamento de hiperplasia benigna da próstata com sarms.
EP1534707B9 (en) * 2002-06-19 2008-11-26 Janssen Pharmaceutica N.V. Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
WO2004113300A1 (ja) * 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
EP1706404A2 (en) 2004-01-23 2006-10-04 Chiron Corporation Tetrahydrocarboline compounds as anticancer agents
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
EP1737461B1 (en) * 2004-03-15 2012-12-12 PTC Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
EP1829874B1 (en) * 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
EP2324886A1 (en) * 2005-07-29 2011-05-25 Concert Pharmaceuticals Inc. Novel deuterated analogues of tadalafil
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7998971B2 (en) * 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CA2693214A1 (en) * 2007-07-19 2009-01-22 Merck Sharp & Dohme Corp. Beta carboline derivatives as antidiabetic compounds
WO2009073534A2 (en) 2007-11-30 2009-06-11 Maxthera Inc. Bicyclic ppat inhibitors as antibacterial agents
AU2009204048B2 (en) 2008-01-11 2013-08-01 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as MCH antagonists
BRPI0906244A2 (pt) 2008-03-24 2015-06-30 Medivation Technologies Inc Composto, composição farmacêutica, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissores ou um distúrbio neuronal em um indivíduo, uso de um composto e kit
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20120135089A1 (en) * 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8637501B2 (en) 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US20130137705A1 (en) * 2009-09-23 2013-05-30 Sarvajit Chakravarty Pyrido[3,4-b]indoles and methods of use
NZ603575A (en) * 2010-07-06 2014-03-28 Ono Pharmaceutical Co Tetrahydrocarboline derivative
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
TW201309698A (zh) 2011-03-18 2013-03-01 Ono Pharmaceutical Co 四氫咔啉衍生物
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
US10092574B2 (en) 2012-09-26 2018-10-09 Valorisation-Recherche, Limited Partnership Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CN107216327A (zh) * 2017-06-27 2017-09-29 山东大学 5型磷酸二酯酶抑制剂及其制备方法和用途
WO2021046194A1 (en) * 2019-09-03 2021-03-11 The Regents Of The University Of Colorado A Body Corporate Tryptoline-based benzothiazoles and their use as antibiotics and antibiotic resistance-modifying agents
WO2022140744A1 (en) 2020-12-23 2022-06-30 Recurium Ip Holdings, Llc Estrogen receptor modulators

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055203A (en) 1964-09-16 1967-01-18 Ici Ltd -ß-carboline derivatives, a process for their manufacture, and compositions containing them
US4228168A (en) 1978-11-22 1980-10-14 Tanabe Seiyaku Co., Ltd. Azepino [1,2,3-lm]-β-carboline compounds and pharmaceutical composition thereof
NZ194747A (en) 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
DE3752373T2 (de) 1986-10-13 2004-03-25 Asahi Kasei Kogyo K.K. Pyridin-derivate
CS262100B1 (cs) * 1987-07-17 1989-02-10 Protiva Miroslav 1-substituované 2- [ (4-methyl-l-piperazinyl)acetyl ] -2,3,4,9- -tetrahydro-lH-pyrido( 3,4-b)indoly a jejich hydrochloridy
DE3855147D1 (de) 1987-07-20 1996-05-02 Duphar Int Res 8,9-Anellierte 1,2,3,4-Tetrahydro-beta-carbolin-Derivate
FR2619112B1 (fr) * 1987-08-07 1989-11-17 Synthelabo Derives de (piperidinyl-4)methyl-2 benzo(b)furo(2,3-c) pyridines, leur preparation et leur application en therapeutique
US4971974A (en) 1988-06-16 1990-11-20 Neurex Corporation Benzothiophenes as appetite suppressants
EP0386258A4 (en) 1988-08-11 1992-05-13 Asahi Kasei Kogyo Kabushiki Kaisha Tetrahydropyridine derivatives
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
FR2663935A1 (fr) 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
ATE247114T1 (de) * 1994-09-12 2003-08-15 Lilly Co Eli Serotonergische modulatoren
FR2724384B1 (fr) 1994-09-14 1999-04-16 Cemaf Nouveaux derives de la 3,4-dihydro beta-carboline agonistes de la melatonine, leur procede de preparation et leur utilisation a titre de medicament
DE4436190A1 (de) 1994-10-10 1996-04-11 Gerhard Prof Dr Bringmann Halogenierte ß-Carbolin-Derivate, Verfahren zu ihrer Herstellung und Verwendung dieser Substanzen zur Hemmung der Atmungskette
DE4436509A1 (de) 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5968910A (en) * 1994-11-30 1999-10-19 Jan M. R. Balzarini Compositions containing two or three inhibitors of different HIV reverse transcriptases
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
FR2748026B1 (fr) 1996-04-26 1998-06-05 Adir Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3418405B2 (ja) 1996-05-10 2003-06-23 アイコス コーポレイション カルボリン誘導体
US6018046A (en) 1996-05-31 2000-01-25 Mochida Pharmaceutical Co., Ltd. Pyridocarbazole derivatives having cGMP-PDE inhibitory activity
AU6290998A (en) 1997-03-07 1998-09-29 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno{3,2-c}pyridine derivatives, their preparation and use
US6043252A (en) 1997-05-05 2000-03-28 Icos Corporation Carboline derivatives
AU4919099A (en) 1998-07-11 2000-02-01 University Of Bristol, The Compounds having activity at imidazoline receptors
FR2796644B1 (fr) * 1999-07-23 2001-09-07 Adir Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
US6864253B2 (en) 2005-03-08
UA74826C2 (en) 2006-02-15
US20030166641A1 (en) 2003-09-04
US6492358B2 (en) 2002-12-10
CA2409715A1 (en) 2001-11-22
NO20025527D0 (no) 2002-11-18
CN1255403C (zh) 2006-05-10
BG66141B1 (bg) 2011-07-29
ATE256127T1 (de) 2003-12-15
AU6116701A (en) 2001-11-26
AR028576A1 (es) 2003-05-14
WO2001087038A2 (en) 2001-11-22
EP1289985B1 (en) 2003-12-10
NO20025527L (no) 2003-01-16
NZ522731A (en) 2004-09-24
CA2409715C (en) 2010-09-14
JP2003533453A (ja) 2003-11-11
PL205507B1 (pl) 2010-04-30
NO324251B1 (no) 2007-09-17
IL152873A (en) 2012-01-31
DE60101479D1 (en) 2004-01-22
BG107285A (bg) 2003-07-31
SK16972002A3 (sk) 2003-11-04
US20020010189A1 (en) 2002-01-24
PL365445A1 (en) 2005-01-10
AU2001261167B2 (en) 2006-10-05
DK1289985T3 (da) 2004-04-05
ZA200210111B (en) 2004-03-12
KR20030031482A (ko) 2003-04-21
HUP0302412A3 (en) 2007-02-28
MY128479A (en) 2007-02-28
HRP20020910A2 (en) 2004-12-31
WO2001087038A3 (en) 2002-05-16
GEP20053511B (en) 2005-05-10
MXPA02011426A (es) 2004-09-06
ES2211806T3 (es) 2004-07-16
CN1446217A (zh) 2003-10-01
PT1289985E (pt) 2004-03-31
CZ20023934A3 (cs) 2003-10-15
TR200302309T4 (tr) 2004-02-23
JP5014551B2 (ja) 2012-08-29
IL152873A0 (en) 2003-06-24
RU2271358C2 (ru) 2006-03-10
DE60101479T2 (de) 2005-04-28
HUP0302412A2 (hu) 2003-11-28
HRP20020910B1 (en) 2011-02-28
EP1289985A2 (en) 2003-03-12
TWI286553B (en) 2007-09-11

Similar Documents

Publication Publication Date Title
HK1051368A1 (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
IL181957A0 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
AU2001285163A1 (en) Quinoline inhibitors of cgmp phosphodiesterase
AU1025899A (en) Carboline derivatives as cgmp phosphodiesterase inhibitors
AU7392101A (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
HK1056550A1 (en) Xanthine phosphodiesterase v inhibitors
GB0025782D0 (en) Use of inhibitors
PL355022A1 (en) Imidazopyridine derivatives as phosphodiesterase vii inhibitors
AU2954102A (en) (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors
EP1165521A4 (en) FUSED COMPOUNDS OF PYRIDOPYRIDAZINE CGMP PHOSPHODIESTERASE INHIBITORS
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
PL351822A1 (en) Thienopyrimidines as phosphodiesterase inhibitors
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
AU2002224835A1 (en) Dihydroisoquinolines as novel phosphodiesterase inhibitors
SI1289985T1 (en) Beta-carboline derivatives useful as inhibitors of phosphodiesterase
SI1296981T1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
SI1226143T1 (en) Imidazopyridine derivatives used as phosphodiesterase vii inhibitors
AU2002348365A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
SI1268480T1 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150503